2型糖尿病患者应用西格列汀的短期疗效及影响因素

doi:10.6040/j.issn.1671-7554.0.2016.199

摘要/Abstract

摘要： 目的分析2型糖尿病患者应用西格列汀的短期疗效及其影响因素,为临床患者的选择及提高疗效提供依据。方法收集2012年9月至2014年6月住院并应用西格列汀的2型糖尿病患者86例病例资料。根据患者空腹C肽水平四分位数分为C肽水平最高组和C肽水平最低组,每组12例。采用多元线性逐步回归分析患者临床资料中影响血糖下降水平的因素。结果使用西格列汀后,C肽水平最高组与C肽水平最低组空腹血糖(FBG)下降值、餐后2 h血糖(2h-PBG)下降值及百分数差异无统计学意义(P>0.05)。糖化血红蛋白(HbA1c)是影响FBG下降值及下降百分数的独立因素;用药前2h-PBG水平是影响2h-PBG下降值及其下降百分数的独立因素。患者使用西格列汀后,最大日内血糖波动值较使用前减小且低血糖发生显著减少(P<0.05)。结论西格列汀可同时降低患者FBG和2h-PBG,且疗效相当;其对FBG和2h-PBG的疗效不完全依赖于C肽水平;可显著减少血糖波动和低血糖事件的发生。

关键词: 餐后2 h血糖, 2型糖尿病, 西格列汀, 空腹血糖

Abstract: Objective To analyze the factors that affect the efficacy of sitagliptin in the treatment of type 2 diabetic mellitus(T2DM)patients. Methods Clinical data of 86 T2DM patients who treated with sitagliptin during Sept.2012 and June 2014 were collected. According to the levels of fasting C peptide, the patients were divided into two groups: maximum C peptide group(n=12)and minimum C peptide group(n=12). Multiple line regression analysis was performed to analyze the factors that might affect the efficacy of sitagliptin. Results After administration of sitagliptin, there was no significant difference in the decrease of fasting blood glucose(FBG)and 2 h post prandial blood glucose(2h-PBG)between the maximum and minimum C peptide groups(P>0.05). Multiple line regression analysis showed that HbA1c was an independent factor that affected the decrease of FBG; baseline 2h-PBG level was an independent factor that affected the efficacy of sitagliptin on 2h-PBG. Sitagliptin significantly decreased glucose excursion(P<0.05), and reduced episodes of hypoglycemia. Conclusion Sitagliptin decreases both FBG and 2h-PBG. The efficacy of sitagliptin may not entirely depend on C peptide levels. Sitagliptin significantly decreases blood excursion and hypoglycemia.

Key words: Type 2 diabetes mellitus, Sitagliptin, Fasting blood glucose, 2 h post prandial blood glucose

中图分类号:

R574

彭力,强晔,赵蕙琛,陈诗鸿,姚伟东,刘元涛. 2型糖尿病患者应用西格列汀的短期疗效及影响因素[J]. 山东大学学报（医学版）, 2016, 54(8): 60-63.

PENG Li, QIANG Ye, ZHAO Huichen, CHEN Shihong, YAO Weidong, LIU Yuantao. Clinical studies on type 2 diabetic patients treated with sitagliptin[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 60-63.

参考文献

[1] Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2(non-insulin-dependent)diabetes[J]. Diabetologia, 1986, 29(1): 46-52.
[2] Abraham EJ, Leech CA, Lin JC, et al. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells[J]. Endocrinology, 2002, 143(8): 3152-3161.
[3] Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus[J]. Diabetologia, 2005, 48(6): 1168-1172.
[4] 叶潇, 张倩, 曹瑛, 等. 西格列汀与阿卡波糖治疗新诊断2型糖尿病患者的疗效比较[J]. 中国糖尿病杂志, 2012, 8(20): 619-621. YE Xiao, ZHANG Qian, CAO Ying, et al. Comparison of therapeutic effects of sitagliptin versus acarbose for newly-diagnosed T2DM patients[J]. Chin J Diabetes, 2012, 8(20): 619-621.
[5] Giuseppe D, Pietro DR, Elena F, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation[J]. Fund Clin Pharmacol, 2014, 28(2): 221-229
[6] Keiji Y. Efficacy of initial basal-supported oral therapy with sitagliptin in untreated type 2 diabetes[J]. Diabetes Ther, 2013, 4(2): 409-416.
[7] Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes[J]. Diabetes, 2006, 55(6): 1695-1704.
[8] Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats[J]. Diabetes, 2003, 52(3): 741-750.
[9] Yuan GY, Jia J, Zhang CL, et al. Safety and effcacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion(CSII)therapy in patients with newly diagnosed type 2 diabetes[J]. Endocrine Journal, 2014, 61(5): 513-521.
[10] Lu J, Zang J, Li H. Impact of three oral antidiabetic drugs on markers of b-Cell function in patients with type 2 diabetes: A meta-analysis[J]. PLoS One, 8(10): e76713. doi:10.1371/journal.pone.0076713.
[11] Gerald HT. Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors[J]. World J Diabetes, 2014, 5(5): 636-650.
[12] Holst JJ. The physiology of glucagon-like peptide 1[J]. Physiol Rev, 2007, 87(4): 1409-1439.
[13] Urd K, Jens JH, Sten M. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual b-Cell function[J]. Diabetes, 2011, 60(5): 1599-1607.
[14] Behme MT, Dupré J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes[J]. BMC Endocr Disord, 2003, 3(1): 3.
[15] Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36)amide in type I diabetic patients[J]. Diabetes Care, 1996, 19(6): 580-586.
[16] Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitorsitagliptinas monotherapy on glycemic control in patients with type 2 diabetes[J]. Diabetes Care, 2006, 29(12): 2632-2637.
[17] Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers[J]. J Clin Endocrinol Metab, 2002, 87(3): 1239-1246.
[18] PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe non-proliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study(PKC-DRS)multicenter randomized clinical trial[J]. Diabetes, 2005, 54(7): 2188-2197.

相关文章 15

[1]	张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7-14.
[2]	苏萍,杨亚超,杨洋,季加东,阿力木·达依木,李敏,薛付忠,刘言训. 健康管理人群2型糖尿病发病风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 82-86.
[3]	李帅,王雅琳,孙忠文,朱梅佳. Nod样受体蛋白3炎性体在2型糖尿病脑微血管内皮细胞中的变化及变化机制[J]. 山东大学学报（医学版）, 2017, 55(3): 6-11.
[4]	杨洋,张光,张成琪,宋心红,薛付忠,王萍,王丽,刘言训. 基于体检队列的2型糖尿病风险预测模型[J]. 山东大学学报（医学版）, 2016, 54(9): 69-72.
[5]	林栋,管庆波. 2型糖尿病男性患者血清睾酮水平低下对非酒精性脂肪肝的影响[J]. 山东大学学报（医学版）, 2016, 54(7): 33-37.
[6]	木哈达斯·吐尔逊依明,帕它木·莫合买提,托兰古丽·买买提库尔班. CDKAL1(rs10946398 C/A)基因多态性与2型糖尿病易感性关系Meta分析[J]. 山东大学学报（医学版）, 2016, 54(2): 75-85.
[7]	于宁,高燕燕,咸玉欣,牛佳鹏,李莉,王静,曹彩霞. 艾塞那肽对2型糖尿病合并非酒精性脂肪肝患者肝脏脂肪含量及血清chemerin水平的影响[J]. 山东大学学报（医学版）, 2016, 54(11): 51-55.
[8]	张莉,朱惠明,王艳梅,江堤,孙贤久,乐有林. 2型糖尿病患者腹胀与小肠细菌过度生长的关系[J]. 山东大学学报（医学版）, 2016, 54(1): 45-47.
[9]	刘言训, 刘佳, 张涛, 王璐, 薛付忠, 王萍. 基于纵向监测队列的2型糖尿病与甲状腺结节的关联性[J]. 山东大学学报（医学版）, 2015, 53(8): 83-86.
[10]	裴蕾蕾, 孙中华, 李哲, 赵文萍. 西格列汀联合大剂量胰岛素治疗2型糖尿病的临床观察[J]. 山东大学学报（医学版）, 2015, 53(2): 39-42.
[11]	胡芳志, 张正军, 耿厚法, 梁秋华, 孙琳. 2型糖尿病患者尿微量白蛋白与脑组织代谢物变化的关系[J]. 山东大学学报（医学版）, 2015, 53(2): 43-47.
[12]	李方. 可溶性晚期糖基化终末产物受体及其基因多态性与2型糖尿病的易感性分析[J]. 山东大学学报（医学版）, 2015, 53(12): 57-61.
[13]	秦祥德, 杨春云, 张媛, 倪一虹, 于超, 冯晓丽, 徐成伟. 2型糖尿病合并下肢骨折患者凝血分子标志物的变化及其与血栓形成的关系[J]. 山东大学学报（医学版）, 2015, 53(11): 55-58.
[14]	李寒冰, 高燕燕, 李莉, 曹彩霞, 咸玉欣, 王静, 牛佳鹏. 兰索拉唑与艾塞那肽联用对2型糖尿病患者胃泌素及胃泌酸调节素的影响[J]. 山东大学学报（医学版）, 2015, 53(11): 64-68.
[15]	潘娟, 胡慧. 系统性红斑狼疮合并2型糖尿病1例个案管理报道[J]. 山东大学学报（医学版）, 2014, 52(S2): 64-65.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed